Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells

Leukemia

Volumn 18, Issue 4, 2004, Pages 798-808

  Kloosterboer, F M ^a   van Luxemburg Heijs, S A P ^a   van Soest, R A ^a   Barbui, A M ^b   van Egmond, H M ^a   Strijbosch, M P W ^a   Kester, M G D ^a   Marijt, W A F ^a   Goulmy, E ^a   Willemze, R ^a   Falkenburg, J H F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Donor lymphocyte infusion; Graft versus leukemia; Immunodominance; Minor histocompatibility antigen

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN HA 1; MINOR HISTOCOMPATIBILITY ANTIGEN HA 2; PEPTIDE; T LYMPHOCYTE RECEPTOR; TETRAMER; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANALYTIC METHOD; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CELL COUNT; CELL GROWTH; CELL ISOLATION; CELL SPECIFICITY; CLONAL VARIATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DONOR; DONOR LYMPHOCYTE INFUSION; FEMALE; FREQUENCY ANALYSIS; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STEM CELL; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TIME; TREATMENT OUTCOME;

EID: 6344238438     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403297     Document Type: Article

References (50)

1. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
2. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
3. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
4. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
5. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139-145.
6. Peggs KS, Mackinnon S. Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol 2001; 8: 349-354.
7. Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. Curr Opin Oncol 2001; 13: 95-100.
8. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
9. de Bueger M, Bakker A, van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788-1794.
10. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996; 8: 75-81.
11. Brickner AG, Warren EH, Caldwell JA, Akatsuka Y, Golovina TN. Zarling AL et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001; 193: 195-205.
12. Vogt MH, de Paus RA, Voogt PJ, Willemze R, Falkenburg JH. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood 2000; 95: 1100-1105.
13. Vogt MH, Goulmy E, Kloosterboer FM, Blokland E, de Paus RA, Willemze R et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000; 96: 3126-3132.
14. Vogt MH, van den Muijsenberg JW, Goulmy E, Spierings E, Kluck P, Kester MG et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-3032.
15. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y. Blokland E et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588-1590.
16. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997; 6: 273-281.
17. Warren EH, Gavin MA, Simpson E, Chandler P, Page DC, Disteche C et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000; 164: 2807-2814.
18. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-1057.
19. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476-1480.
20. Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensink E et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301-308.
21. van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, Luxemburg-Heijs SA, Goselink HM et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060-1066.
22. Falkenburg JH, Goselink HM, van der Harst D, Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27-33.
23. Faber LM, Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821-2828.
24. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 8639-8644.
25. Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J 2001; 2: 363-370.
26. Wilke M, Dolstra H, Maas F, Pool J, Brouwer R, Frederik Falkenburg JH et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies. Hematol J 2003; 4: 315-320.
27. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
28. Tseng LH, Lin MT, Hansen JA, Gooley T, Pei J, Smith AG, Martin EG et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1999; 94: 2911-2914.
29. van Lochem E, van der Keur M, Mommaas AM, de Gast GC, Goulmy E. Functional expression of minor histocompatibility antigens on human peripheral blood dendritic cells and epidermal Langerhans cells. Transpl Immunol 1996; 4: 151-157.
30. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
31. Dickinson AM, Wang XN, Svlland L, Vyth-Dreese FA, Jackson GH, Schumacher TN et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410-414.
32. van Els CA, D'Amaro J, Pool J, Blokland E, Bakker A, van Eisen PJ et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 1992; 35: 161-165.
33. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999; 5: 839-842.
34. Rufer N, Wolpert E, Helg C, Tiercy JM, Gratwohl A, Chapuis B et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation 1998; 66: 910-916.
35. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, Van Der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747.
36. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Geurts van Kessel A et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
37. Beverstock GC, de Meijer PH, ten Bokkel Huinink D, Pruijt JF, den Ottolander GJ, Wessels HW et al. A case of isodicentric 7p as sole abnormality in a patient with acute myeloid leukemia. Cancer Genet Cytogenet 1996; 89: 132-135.
38. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000; 165: 6229-6234.
39. Faber LM, Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
40. Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 1998; 95: 10152-10157.
41. Van Der Hoorn MA, Luxemburg-Heijs SA, van Bergen CA, Bongaerts R, Willemze R, Falkenburg JH. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. Methods 2003; 31: 113-119.
42. Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, Van Der Hoorn MA, Goulmy E et al. Redirection of anti-leukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003; 102: 3530-3540.
43. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455-500.
44. Cluitmans FH, Esendam BH, Landegent JE, Willemze R, Falkenburg JH. IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes. Ann Hematol 1994; 68: 293-298.
45. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000; 165: 6644-6652.
46. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7: 1159-1162.
47. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002; 62: 1743-1750.
48. Goulmy E, Pool J, van den Elsen PJ. Interindividual conservation of T-cell receptor beta chain variable regions by minor histocompatibility antigen-specific HLA-A*0201-restricted cytotoxic T-cell clones. Blood 1995; 85: 2478-2481.
49. Verdijk RM, Mutis T, Wilke M, Pool J, Schrama E, Brand A et al. Exclusive TCRVbeta chain usage of ex vivo generated minor histocompatibility antigen HA-1 specific cytotoxic T cells: implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping. Hematol J 2002; 3: 271-275.
50. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.